2026 ACS Prostate Screening Recommendations: PSA Intervals and Follow-Up
Key Takeaways
- The 2026 American Cancer Society (ACS) guideline recommends PSA-based screening every 2 years for average-risk men aged 50–69, replacing its 2010 approach, which left screening to shared decision making, with a direct screening recommendation.
- Men with a strong family history are advised to begin annual screening at 45; non-Black men with one first-degree relative diagnosed at 65 or older are advised to begin biennial screening at 45.
- Screening decisions are individualized at ages 70–74, and screening is not recommended at 75 or older or at any age with life expectancy under 10 years.
- Most men whose elevated PSA is confirmed on repeat testing should be offered MRI and/or a validated high-sensitivity biomarker to guide the biopsy decision.
The ACS Guideline Development Group drew on a systematic evidence review of randomized trials and observational studies and commissioned three Cancer Intervention and Surveillance Modeling Network (CISNET) teams to project lifetime outcomes of alternative screening strategies. Recommendations were graded A through D or issued as ungraded consensus statements when evidence was limited or indirect. They do not apply to men with known or suspected hereditary cancer syndromes, such as BRCA2 mutations, for whom specialty guidelines apply.
For average-risk men, defined as non-Black men without a family history of prostate cancer, the ACS recommends screening every 2 years from ages 50 through 69 (B recommendation, moderate certainty of evidence). For Black men, it recommends annual screening from 45 through 69; the starting age is graded B (low certainty), and the annual interval is a consensus statement. Annual screening from 45 through 69 is also recommended for non-Black men with a strong family history, and biennial screening from 45 through 69 for non-Black men with a single first-degree relative diagnosed at 65 or older; both are consensus statements. The ACS recommends against digital rectal examination as a primary screening test (D recommendation, high certainty).
For men aged 70–74, the ACS recommends individualized decisions based on overall health, values, and preferences (C recommendation, low certainty). Men who choose screening should be tested every 2 years through age 74, and screening may stop after any PSA value below 3 ng/mL. Screening is not recommended at 75 or older or at any age with life expectancy under 10 years (D recommendation, low certainty). Some very healthy men aged 75–79 with a rising PSA may continue after discussing the lack of evidence of benefit, but screening beyond 80 should be discouraged.
A PSA of 3.0 ng/mL or higher at ages 69 and younger, or 6.5 ng/mL or higher at ages 70–74, should be repeated, preferably 2 weeks to 3 months later, before further evaluation. Most men whose elevated result is confirmed should be offered MRI and/or a validated biomarker with high sensitivity for clinically significant cancer to guide the biopsy decision, although urologists may proceed directly to biopsy in situations such as a suspicious rectal examination or markedly elevated PSA. Men diagnosed with low-risk cancer should initially be offered active surveillance. All three are consensus statements.
At 23 years of follow-up, the ERSPC reported a 13% relative reduction in prostate cancer mortality among men aged 55–69 (rate ratio 0.87; 95% confidence interval 0.80–0.95). The absolute risk reduction grew from 0.07% to 0.22% with longer follow-up, and the number needed to invite to prevent one death fell from 1,410 to 456. In the CISNET models, biennial screening at ages 50–69 with secondary MRI projected 14–16 lives saved and 17–41 overdiagnoses per 1,000 men. Applying the same strategy to Black men, the models projected 28–36 lives saved and 22–65 overdiagnoses. The evidence review rated the overall strength of evidence for mortality reduction as low, reflecting differences across trials. The guideline panel nonetheless judged that the evidence supports moderate certainty of net benefit for average-risk men.
Black men were underrepresented in PLCO, and the ERSPC did not report the number of Black participants, so recommendations for Black men and for men with a family history rely largely on modeling and are partly issued as consensus statements. The models assumed full adherence and no difference in screening or treatment efficacy by race, ethnicity, or family history. The trials do not reflect contemporary MRI- and biomarker-based pathways, and no single biomarker has emerged as preferred. The magnitude of overdiagnosis cannot be estimated with confidence, and the 6.5 ng/mL threshold may not capture men with a rising PSA below that level.
The ACS concludes that the benefits of PSA-based screening outweigh its harms and incorporates repeat testing, secondary evaluation before biopsy, and active surveillance to reduce those harms. It describes the guideline as a living document to be updated as evidence evolves.
Clinician Questions
What counts as a strong family history of prostate cancer under the 2026 ACS guideline?
A strong family history means multiple first-degree relatives diagnosed with prostate cancer at any age, or one first-degree relative diagnosed before age 65. These men are advised to begin annual screening at 45. Non-Black men with a single first-degree relative diagnosed at 65 or older fall into a separate category, with biennial screening from 45.
What should men be told before starting PSA screening under the 2026 ACS guideline?
Clinicians should ensure that men understand the benefits, limitations, and harms of PSA-based screening; the follow-up evaluations that may occur after an elevated PSA; and the expectation that low-risk cancers will initially be managed with active surveillance. For men younger than 70, the discussion should include a recommendation for screening, and PSA testing should not be ordered without the patient’s agreement.
This content is intended for healthcare professionals for educational purposes. The article and its image were developed with AI assistance and reviewed by members of the ReachMD team prior to publication. Please refer to the original source linked for the complete and most up-to-date information.